Patients receiving biological response modifiers: overview of nursing care
Irwin, M.M.
Oncology Nursing Forum 14(6 Suppl): 32-37
1987
ISSN/ISBN: 0190-535X PMID: 2447571 Document Number: 304182
Document emailed within 1 workday
Related Documents
Ackermann, R. 1988: Biological response modifiers in renal cancer Progress in Clinical and Biological Research 269: 313-328Ishihara, K. 1989: On the behalf of the Japanese Society of Biological Response Modifiers Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(4 Pt 2-1): 906-911
Okawa, T.; Goto, M.; Kita, M. 1987: Radiotherapy combined with BRM (biological response modifiers) in the treatment of cancer Gan no Rinsho. Japan Journal of Cancer Clinics 33(10): 1253-1256
Kirkpatrick, C.H. 1989: Biological response modifiers. Interferons, interleukins, and transfer factor Annals of Allergy 62(3): 170-176
Zlotta, A.R.; Schulman, C.C. 2000: Biological response modifiers for the treatment of superficial bladder tumors European Urology 37(Suppl): 10-15
Scheinberg, M.A. 1988: Clinical trials with biological response modifiers in rheumatic diseases Journal of Rheumatology 15(7): 1056-1057
Muss, H.B. 1988: The role of biological response modifiers in metastatic renal cell carcinoma Seminars in Oncology 15(5 Suppl 5: 30-34
Saito, A. 2001: A putative immunotherapy with biological response modifiers (BRM) against intractable pulmonary tuberculosis Kekkaku: 76(12): 741-747
Koga, H.; Miyazaki, Y.; Kohno, S.; Hara, K. 1994: A drug delivery system and biological response modifiers for the treatment of mycobacterial infection Kekkaku: 69(2): 113-118
Talmadge, J.E.; Herberman, R.B. 1986: The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiers Cancer Treatment Reports 70(1): 171-182
Bergmann, L. 1989: Malignant melanoma--prognosis and actual treatment strategies with chemotherapy and biological response modifiers European Journal of Cancer and Clinical Oncology 25(Suppl 3): S31-S36
Nio, Y.; Zighelboim, J.; Berek, J.S.; Bonavida, B. 1990: Augmentation of cytotoxicity of lymphokine activated killer cells on ovarian tumor cells by various biological response modifiers Anticancer Research 10(2a): 441-446
Sodhi, A.; Pai, K. 1992: Studies on the release of interleukin-1 (IL-1), tumor necrosis factor (TNF) and lysozyme from human non-adherent mononuclear cells (nMNC) in vitro after treatment with cisplatin and other biological response modifiers Neoplasma 39(4): 211-217
Xiao, C.M. 1989: Nursing care of adult patients receiving splenic cell homoplastic transplantation (infusion method) Zhonghua Hu Li Za Zhi 24(11): 647-648
Hart, C.N.; Rasmussen, D. 1982: Patient care evaluation: a comparison of current practice and nursing literature for oral care of persons receiving chemotherapy Oncology Nursing Forum 9(2): 22-27
Rikard, D.H. 1993: Nursing care of the neonate receiving prostaglandin E1 therapy Neonatal Network: Nn 12(4): 17-22
Sticklin, L.A.; Dubbelde, K.; Larson, E. 1989: Nursing care of the patient receiving subcutaneous low-dose Ara-C therapy Oncology Nursing Forum 16(3): 365-369
Mulford, E. 1987: Nursing perspectives for the patient receiving postoperative ventricular assistance in the critical care unit Heart and Lung: the Journal of Critical Care 16(3): 246-257
Guan, X.M. 1994: Checking and recording patients' call rate to promote nursing quality of patients receiving intravenous drips Zhonghua Hu Li Za Zhi 29(7): 415-417
Pawłowska, M.łg. 2005: HCV: immune response and its modifiers in clinical development Przeglad Epidemiologiczny 59(2): 519-523